PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT02732171
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Research Blood Collection — OTHER
    Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)

Study Details

This is a single center, prospective cross-sectional study of women who have completed therapy for primary breast cancer within 5 years of diagnosis and are at increased risk for relapse. Patients will undergo screening bone marrow aspirate to test for presence of disseminated tumor cells (DTCs) Patients who harbor DTCs will be offered the opportunity for enrollment into a clinical trial of therapy targeting DTCs to prevent recurrence (separate protocols).

Key Dates

Start date
Apr 30, 2016
Status verified
Jul 2025
Primary completion
Apr 30, 2028
Completion
Apr 30, 2030

Study Design

Enrollment
600 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING

Arms

  • Other: Screening Bone Marrow Aspirate
    All patients will undergo screening bone marrow aspirate to test for disseminated tumor cells (DTCs) by immunohistochemistry. The bone marrow sample is also used for other research tests.

Primary Outcome Measure

Incidence and frequency of disseminated tumor cells [ Time Frame: DTCs will be assessed annually up to 5 years from date of primary diagnosis ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Abramson Cancer Center of the University of PennsylvaniaPhiladelphiaPennsylvania19104
Angela DeMichele, MD
[email protected]
855-216-0098

Find similar trials in Philadelphia, PA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Abramson Cancer Center of the University of Pennsylvania· Philadelphia, PA

Related Studies